Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBunzl Regulatory News (BNZL)

Share Price Information for Bunzl (BNZL)

Share Price is delayed by 15 minutes
Get Live Data
2,420.00    30.00 (1.26%)
Bid:
2,412.00
Ask:
2,414.00
Spread: 2.00 (0.083%)
Market Cap: £7.77b
BNZL Live PriceLast checked at - London Stock Exchange

Intraday Bunzl Share Chart

Trading Statement

17 Dec 2024 07:00

RNS Number : 2837Q
Bunzl PLC
17 December 2024
 

17 December 2024

BUNZL PRE-CLOSE STATEMENT

 

Bunzl plc, the specialist international distribution and services Group, is updating the market today prior to entering its closed period for the year ending 31 December 2024.

 

Group revenue in 2024 is expected to be approximately 3% higher than in 2023, at constant exchange rates, and between 0% and 1% lower at actual exchange rates. Group revenue growth at constant exchange rates is expected to be driven by acquisitions, and with a small decline in underlying revenue over the year. Within underlying revenue, volume growth in the third quarter is expected to continue in the fourth quarter, although deflation is likely to be more persistent than previously anticipated. This is expected to have a slight impact on Group adjusted operating profit in 2024, driven by Continental Europe. Group adjusted operating profit in 2024 will represent a strong increase in comparison with 2023 at constant exchange rates. Expected Group operating margin for 2024 is strong and continues to be moderately above the level reported for 2023.

 

Looking ahead, despite uncertainties relating to the wider economic and geopolitical landscape, the Group expects robust revenue growth in 2025, at constant exchange rates, driven by announced acquisitions and slight underlying revenue growth. Group operating margin is expected to be maintained in-line with 2024 and to remain substantially higher compared to pre-pandemic levels, driven by higher margin acquisitions, as well as a good underlying margin increase.

 

In August 2024, we made a commitment to allocate c.£700 million per annum, primarily to be invested in value-accretive acquisitions and, if required, returns of capital in each of the three years ending 31 December 2027, which is intended to steadily return Bunzl to its target leverage range by the end of 2027. Alongside this, Bunzl has demonstrated the strength of its acquisition pipeline, with 2024 a record year for committed spend of more than £850 million. We also initiated a £250 million buyback in August, of which approximately £200 million has now been completed. In addition, we confirm that a further £200 million buyback will be executed during 2025, as previously outlined.

 

In October, Bunzl completed the acquisition of the C&C Group ("C&C"), a specialist foodservice business that complements our existing commercial catering businesses in the UK. The business generated revenue of £26 million in the year to April 2024.

 

In December, Bunzl completed the acquisition of Comodis, a leading distributor of cleaning and hygiene products in the Rhône-Alpes region of France, strengthening our presence in this region. This business generated revenue of EUR 23 million (c.£20 million) in the year to March 2024.

 

Commenting on today's announcement, Frank van Zanten, Chief Executive Officer of Bunzl, said:

 

"2024 will be another year of significant progress for Bunzl, demonstrating the continued growth and resilience of the business model. The Group is expected to deliver a strong increase in Group adjusted operating profit year-on-year, alongside a Group operating margin that has expanded over recent years. We continue to execute on our capital allocation commitments, and welcome C&C and Comodis to the Group, enhancing our offerings in the UK and France, whilst also confirming a further £200m share buyback over 2025. Overall, during 2024 the Group has committed a record spend of more than £850 million with 13 announced acquisitions year-to-date, and our pipeline remains active."

 

Enquiries:

 

Bunzl plc

Frank van Zanten, Chief Executive Officer

Richard Howes, Chief Financial Officer

Sunita Entwisle, Head of Investor Relations

Tel: +44 (0)20 7725 5000

Teneo

Martin Robinson

Olivia Peters

Tel: +44 (0)20 7353 4200

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBLBDDLBBDGSL
Date   Source Headline
1st Apr 202211:13 amRNSTotal Voting Rights
17th Mar 20224:15 pmRNSAnnual Financial Report
15th Mar 202211:30 amRNSDirector Declaration
3rd Mar 20225:07 pmRNSDirector/PDMR Shareholding
2nd Mar 20226:12 pmRNSDirector/PDMR Shareholding
2nd Mar 20225:36 pmRNSDirector/PDMR Shareholding
1st Mar 20225:58 pmRNSDirector/PDMR Shareholding
1st Mar 20223:00 pmRNSTotal Voting Rights
1st Mar 20229:00 amRNSDirector Declaration
28th Feb 20227:00 amRNSAnnual Financial Report
3rd Feb 20224:06 pmRNSDirector/PDMR Shareholding
2nd Feb 20225:30 pmRNSDirectorate Change
1st Feb 202210:58 amRNSTotal Voting Rights
12th Jan 202212:15 pmRNSDirector/PDMR Shareholding
12th Jan 20227:00 amRNSAcquisition
10th Jan 20225:34 pmRNSDirector/PDMR Shareholding
7th Jan 202211:54 amRNSDirector/PDMR Shareholding
4th Jan 20225:56 pmRNSTotal Voting Rights
15th Dec 20217:00 amRNSTrading Statement
10th Dec 20213:18 pmRNSDirector/PDMR Shareholding
8th Dec 20214:30 pmRNSDirector Declaration
8th Dec 20218:00 amRNSAdditional Listing
3rd Dec 20214:27 pmRNSDirector/PDMR Shareholding
1st Dec 20214:50 pmRNSDirector/PDMR Shareholding
1st Dec 202110:20 amRNSTotal Voting Rights
18th Nov 20217:00 amRNSAcquisition
10th Nov 20213:00 pmRNSPublication of Admission Particulars
4th Nov 20215:41 pmRNSDirector/PDMR Shareholding
3rd Nov 202112:35 pmRNSDirector/PDMR Shareholding
3rd Nov 202112:35 pmRNSDirector/PDMR Shareholding
1st Nov 20213:14 pmRNSTotal Voting Rights
1st Nov 20219:00 amRNSBlock listing Interim Review
29th Oct 20211:10 pmRNSDirector/PDMR Shareholding
26th Oct 20217:00 amRNSTrading Statement
19th Oct 20215:12 pmRNSDirector/PDMR Shareholding
19th Oct 20215:11 pmRNSDirector/PDMR Shareholding
11th Oct 20217:00 amRNSCapital Markets Day
8th Oct 20212:28 pmRNSDirector/PDMR Shareholding
8th Oct 20212:24 pmRNSDirector/PDMR Shareholding
5th Oct 202110:16 amRNSDirector/PDMR Shareholding
1st Oct 202112:36 pmRNSTotal Voting Rights
14th Sep 20217:00 amRNSAcquisition
3rd Sep 202112:30 pmRNSDirector/PDMR Shareholding
1st Sep 20214:00 pmRNSTotal Voting Rights
31st Aug 20214:30 pmRNSDividend Declaration
31st Aug 20217:00 amRNSHalf-year Report
31st Aug 20217:00 amRNSAcquisition
4th Aug 202111:24 amRNSDirector/PDMR Shareholding
2nd Aug 20213:40 pmRNSTotal Voting Rights
14th Jul 20214:11 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.